Abstract 39P
Background
This study aims to investigate the immunohistochemical expression of HIF-1α, GLUT1, and CA IX in patients with invasive ductal breast cancer (IDC) and assess their correlation with the maximum standardized uptake value of the primary tumor (pSUVmax) and other biological parameters. Additionally, the prognostic significance of pSUVmax, HIF-1α, GLUT1, and CA IX in predicting progression-free survival (PFS) will be evaluated.
Methods
A total of 174 female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled in this study. The pSUVmax was compared with clinicopathological parameters, including estrogen receptor (ER), progesterone receptor (PR), HER2 status, axillary lymph node metastasis (LNM), cancer stage, GLUT1, CA IX, and HIF-1α. The prognostic value of pSUVmax, GLUT1, CA IX, and HIF-1α for PFS was analyzed using the Kaplan-Meier method.
Results
The study revealed that pSUVmax was significantly higher in patients with HIF-1α≥2, GLUT1≥5, and CA IX≥3, compared to patients with HIF-1α<2, GLUT1<5, and CA IX<3 (4.9±4.1 vs. 3.9±3.2, P=0.02; 6.1±4.2 vs. 3.5±3.0, P=0.003; 5.9±4.5 vs. 3.8±3.2, P=0.003). Furthermore, patients with disease progression had significantly higher pSUVmax values than those who remained disease-free (6.4±3.5 vs. 4.1±3.6, P=0.0045). Receiver-operating characteristic (ROC) curve analysis identified optimal cutoff values for predicting PFS as pSUVmax of 6.8, GLUT1 of 5, and CA IX of 3, with corresponding sensitivities and specificities. Kaplan-Meier analysis revealed that pSUVmax ≥6.8 (P=0.0004), GLUT1≥5 (P=0.0005), and CA IX≥3 (P<0.0001) were predictive of recurrence.
Conclusions
The study findings indicate that pSUVmax on pretreatment F-18 FDG PET/CT can serve as a reliable surrogate marker for predicting progression in patients with IDC. Increased FDG uptake is associated with higher expression levels of HIF-1α, GLUT1, and CA IX, indicating the presence of glucose metabolism and hypoxia in breast cancer cells. These biomarkers hold promise for improved cancer detection and prognostication in IDC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract